17DD Yellow Fever Vaccine Is Immunogenic in a Dengue-Endemic Area

All vaccine recipients, including those with earlier dengue infection, developed protective antibodies.

Yellow fever (YF) virus is a potential threat to large urban centers in Brazil, where competent mosquito vectors thrive and dengue fever (caused by a closely related flavivirus) has proliferated in recent decades. The 17DD YF vaccine is manufactured in Brazil; about 85 million doses were administered there between 1990 and 2000. Few studies have assessed this vaccine, and little is known about how previous dengue infection might affect immune response to YF preparations. To address these issues, researchers conducted a pair of studies — one prospective and the other retrospective — in Recife, Brazil.

In the prospective study, which involved healthy YF vaccine–naive individuals, the investigators obtained blood samples before and for as long …

Reviewing Author

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine